This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Inclusion Criteria:
Exclusion Criteria:
Semaglutide 6 mg liquid emulsion formulation daily
Placebo liquid emulsion formulation daily
Wegovy (semaglutide) 25 mg Tablet daily after 90 day titration
Minneapolis, Minnesota 55402, United States
gdb@allergy-asthma-docs.com612-333-2200
KW@allergy-asthma-docs.com612-333-2200
Latino Semaglutide Study
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
A Study of a Novel Precision Medicine Approach For Obesity
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Semaglutide Treatment in Type 1 Diabetes
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range